- Phys.org· 2 days ago
Researchers have used plants to produce virus-like particles (VLPs) of the dengue virus in a potential first step towards novel vaccines against the growing threat.
- Benzinga.com· 1 day ago
The "Dengue Vaccines" report has been added to ResearchAndMarkets.com's offering. The dengue vaccines market is
- IFLScience· 2 weeks ago
As the weather cools, the number of infections of the COVID-19 pandemic are rising sharply....
- Phys.org· 2 days ago
Sep 23, 2019 · Dengue Vaccine Globally A vaccine to prevent dengue (Dengvaxia®) is licensed and available in some countries for people ages 9-45 years old. The World Health Organization recommends that the vaccine only be given to persons with confirmed prior dengue virus infection.
Dengue vaccine is a vaccine used to prevent dengue fever in humans. As of 2019, one version is commercially available, known as CYD-TDV, and sold under the brand name Dengvaxia. The vaccine is only recommended in those who have previously had dengue fever or populations in which most people have been previously infected.
CYD-TDV is the first dengue vaccine to be licensed. It was first licensed in Mexico in December 2015 for use in individuals 9-45 years of age living in endemic areas, and is now licensed in 20 countries. CYD-TDV is a live recombinant tetravalent dengue vaccine developed by Sanofi Pasteur (CYD-TDV), given as a 3-dose series on a 0/6/12 month ...
2 days ago · Researchers have used plants to produce virus-like particles (VLPs) of the dengue virus in a potential first step towards novel vaccines against the growing threat. Dengue is a pathogenic mosquito ...
- FDA approves dengue vaccine with strict rulesyoutube.com
- June 2019 ACIP Meeting - Dengue Vaccineyoutube.com
- A made-in-India dengue vaccine? It could take 5 years, say scientistsyoutube.com
- February 2020 ACIP Meeting - Dengue Vaccineyoutube.com
Nov 06, 2019 · To test their new vaccine, which is based on a weakened strain of the dengue virus, Wallace and colleagues randomly distributed it or a placebo to 20,000 children, aged 4 to 16, in eight countries...
The FDA approved a vaccine for dengue virus, which causes dengue fever, it said yesterday in a statement. The vaccine, called Dengvaxia, was previously approved in the European Union and 19 other...
- Maggie O'neill
- 1 min
A tetravalent vaccine is urgently needed and must be effective against all four dengue virus serotypes, be cost-effective and provide long-term protection.
- Stephen S. Whitehead, Joseph E. Blaney, Anna P. Durbin, Brian R. Murphy
The study authors hypothesized that a safe and effective dengue vaccine could offer some immunity against SARS-CoV-2 before a coronavirus vaccine is available.